Wockhardt India operates in 6 strategic business units with coverage across different specialities with a strong field force and a robust distribution Pan India. We have completed 2 decades of providing specialised care with our flagship brands – Wosulin (Diabetes), Glimaday (Metabolics), Wepox (Nephrology) and Methycobal (Pain management).

We provide comprehensive Diabetes care with India’s 1st recombinant Human Insulin (Wosulin), long acting Insulin Glargine (Glaritus) and oral antidiabetic drugs. Wockhardt is the only Indian Pharma company to launch novel NCE in India.  Emrok and Emrok O are India’s 1st research patented drugs launched for treatment of MDR Gram Positive Infections. More than 30,000 patients have been successfully treated till date with India’s NCE. Methycobal is the preferred Mecobalamine brand trusted by more than 10,000 Doctors for pain management in Orthopaedics and Neurology segment. Nephrology portfolio has been an integral part of Wockhardt with special focus on Kidney Disease and Kidney Transplant patients. Wepox is the leading Erythropoietin Brand with the trust of more than 5000 CKD Patients and 1500 Nephrologists across India. Wockhardt also provides healthcare in Tier 2 cities with Spasmo Proxyvon Plus and Spasmo Proxyvon T+ in spasmodic pain segment and Decdan in steroids segment.

With our focussed chronic and acute portfolio, we are committed to provide innovative and patient-centric solutions to make a profound impact on the healthcare landscape in India.